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KOOPMANS, S. J., S. F. DE BOER, H. C. M. SIPS, J. K. 
RADDER, M. FR~LICH, AND H. M.J. KRANS. whole body and 
hepatic insulin action in normal, starved, and diabetic rats. Am. 
J. Physiol. 260 (Endocrinol. Metab. 23): E825-E832,1991.-In 
normal (N), 3-days starved (S), and streptozotocin-treated (65 
mg/kg) 3-days diabetic (D) rats we examined the in vivo dose- 
response relationship between plasma insulin levels vs. whole 
body glucose uptake (BGU) and inhibition of hepatic glucose 
production (HGP) in conscious rats, as determined with the 
four-step sequential hyperinsulinemic euglycemic clamp tech- 
nique, combined with [3-“HIglucose infusion. Twelve-hour fast- 
ing (basal) HGP was 3.0 t 0.2, 2.1 t 0.2, and 5.4 t 0.5 mg/min 
in N, S, and D rats, respectively. Next, all rats were clamped 
at matched glycemia (6 mM). Lowering plasma glucose in D 
rats from t20 to 6.0 mM did not increase plasma norepineph- 
rine, epinephrine, glucagon, and corticosterone levels. For 
BGU, insulin sensitivity was increased (70 t 11 pU/ml) in S 
and unchanged (113 t 21 pU/ml) in D compared with N rats 
(105 t 10 pU/ml). Insulin responsiveness was unchanged (12.4 
t 0.8 mg/min) in S and decreased (8.5 t 0.8 mg/min) in D 
compared with N rats (12.3 t 0.7 mg/min). For HGP, insulin 
sensitivity was unchanged (68 t 10 pU/ml) in S and decreased 
(157 t 21 pU/ml) in D compared with N rats (71 t 5 ,uU/ml). 
Insulin responsiveness was identical among N, S, and D rats 
(complete suppression of HGP). In summary, 1) insulin resist- 
ance in D rats is caused by hepatic insensitivity and by a 
reduction in BGU responsiveness. 2) S rats show normal he- 
patic insulin action, but insulin sensitivity for BGU is in- 
creased. Therefore, S and D rats both suffering from a compa- 
rable catabolic state (lo-15% body wt loss in 3 days) show 
opposite effects on in vivo insulin action. This indicates that 
in vivo insulin resistance in D rats is not caused by the catabolic 
state per se. 
norepinephrine; epinephrine; glucagon; corticosterone; glucose 
uptake; glucose production; clamp; catabolism 
BOTH STARVATION and streptozotocin-induced insulin- 
deficient diabetes are accompanied by insulinopenia, re- 
duced glucose metabolism, increased lipolysis, and a state 
of catabolism. In the past decade, a large amount of in 
vitro studies have examined insulin-sensitive tissues iso- 
lated from normal, starved, and diabetic rodents to com- 
pare and characterize the cellular alterations in insulin- 
mediated glucose metabolism. Most studies reveal that 
adipose tissue from starved and diabetic rodents is re- 
sistant to the action of insulin (16, 17, 44). However, 
data obtained from skeletal muscle are less uniform. It 
seems that muscle becomes insulin resistant when the 
diabetic state reaches a certain degree of severity and/or 
lasts for a prolonged time (11, 22, 25, 42). During star- 
vation, insulin action in muscle was reported to be un- 
altered or even increased (10, 22). From the foregoing, it 
is concluded that individual tissues can respond in dif- 
ferent ways to altered metabolism, and one single tissue 
might not reflect the in vivo whole body situation. In- 
deed, the latter has been confirmed in two studies (24, 
46) 
Recently, several laboratories have adapted the hyper- 
insulinemic glucose clamp technique to rats for measure- 
ment of whole body insulin-mediated glucose uptake in 
vivo. In vivo insulin resistance was reported to be present 
in diabetic rats (28,34), however, others could not detect 
a defect in insulin action (4, 18). Two studies were 
performed using starved rats, and one showed a reduction 
in insulin-mediated glucose disposal (29), whereas the 
other was unable to detect any in vivo insulin resistance 
(20) 
By analysis of the in vitro and in vivo results, an 
inconsistent and incomplete picture is obtained. Apart 
from prevailing glycemia, it has been suggested that time 
span and severity of the catabolic state during starvation 
and diabetes and nutritional condition of the rats at the 
start of starvation and diabetes are important factors 
that determine the ultimate effect of starvation and 
diabetes on insulin-mediated metabolism (2, 8, 9, 25). 
Therefore the importance of a standardized comparative 
study using normal, starved, and diabetic rats is stressed. 
The aim of the present investigation was to determine 
the in vivo dose-response relationship between plasma 
insulin levels vs. stimulation of whole body glucose up- 
take and inhibition of hepatic glucose production in 
normal, 3-days starved, and 3days diabetic rats. The 
dose-response study allows us to discriminate between 
in vivo insulin sensitivity and responsiveness. This is 
done to gain a better insight in the mechanism of insulin 
action (31). In vivo insulin action was determined using 
the four-step sequential hyperinsulinemic euglycemic 
clamp technique combined with [3-“HIglucose infusion 
in conscious freely moving rats. 
MATERIALS AND METHODS 
Animals and housing. Male Wistar rats (300-350 g) 
with free access to a complete laboratory rat diet (Hope 
0193-1849/91 $1.50 Copyright 0 1991 the American Physiological Society E825 
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Farms, Woerden, The Netherlands) and water were in- 
dividually housed in Plexiglas metabolic cages (21 x 22 
X 26 cm) at a constant temperature (23°C) and a fixed 
12:12 h light-dark cycle (lights on at 0700 h). 
Surgical procedure. Under complete ether anesthesia, 
rats were provided with two sterile silicon cannulas [Si- 
lastic, medical grade tubing, no. 602-135, inner diameter 
(ID) 0.020 in., outer diameter (OD) 0.037 in.; no. 602- 
105, ID 0.012 in., OD 0.025 in.; Dow Corning, Midland, 
MI]; the large cannula was inserted into the right jugular 
vein for the infusion of fluids, and the smaller was 
inserted into the left carotid artery for blood sampling. 
The tip of the jugular cannula was situated at the en- 
trance of the right atrium and the tip of the carotid 
cannula at the transition of carotid artery and aortic 
arch. Surgical manipulations were performed according 
to the method of Steffens (38), and both cannulas were 
attached to 90” bent steel tubings that were manufac- 
tured from 20-gauge X1.5 needles (Microlance; Becton 
Dickinson, Dublin, Ireland). The two steel tubings were 
fixed on top of the rat skulls by means of four screws (4 
x 1 mm) and dental cement (Simplex rapid; Austenal 
Dental Products, Harrow, UK). The venous catheter was 
filled with a 0.9% NaCl solution containing 0.2 mg/ml 
ticarcillin (Ticarpen; Beecham Farma, Amstelveen, The 
Netherlands), 500 IU/ml heparin (Thromboliquine; Or- 
ganon Teknika, Oss, The Netherlands), and 0.6 g/ml 
polyvinylpyrrolidone (PVP, mol wt = 25,000, Merck). 
The arterial catheter was filled with a 0.9% NaCl solution 
containing 0.2 mg/ml ticarcillin, 500 IU/ml heparin, and 
0.6 g/ml PVP. 
After the dental cement had hardened, the venous line 
was connected to a double-lumen tubing (polyethylene, 
ID 0.016 in., OD 0.040 in.; Talas, Ommen, The Nether- 
lands) by means of a piece of polyethylene tubing (ID 
0.030 in., OD 0.058 in.; Rubber, Hilversum, The Neth- 
erlands). The double-lumen tubing was connected to a 
double-lumen swivel (4l), allowing separate fluid infu- 
sions (i.e., an insulin and [3-3H]glucose solution via one 
channel and a glucose solution through the other chan- 
nel) in the conscious undisturbed freely moving rat. 
Hence, insulin and glucose could be kept separate until 
reaching the skull of the rat, allowing a low infusion rate 
(the insulin and [3-3H]glucose solution infusion rate was 
400 pi/h; the glucose infusion rate was variable). The 
venous double-lumen tubing and the swivel were filled 
with a 0.9% NaCl solution and sealed. The carotid line 
was connected to a polyethylene tubing (ID 0.030 in., 
OD 0.058 in., Rubber), filled with the arterial 0.9% NaCl 
solution with PVP, sealed, and attached aside to the 
lower rotating part of the swivel. Both venous double- 
lumen tubing and arterial blood sampling tubing were 
protected by an outer transparent flexible Tygon tubing 
(ID 0.16 in., OD 0.28 in.). The rat, permanently attached 
to the swivel, was placed in a metabolic cage, and the 
swivel was connected to a contra weight. After surgery, 
the rats were allowed to recover for at least 1 wk before 
the clamp experiments were performed. During this 
period the arterial catheter was aspirated every other day 
to maintain catheter patency and to adapt the rats to 
the clamp and blood-sampling procedure. Within 1 wk 
after surgery the rats reached their preoperative weight 
and were used for the clamp studies. In the present form 
the permanently cannulated rats can be studied for time 
periods up to 4 wk, and catheter patency could be main- 
tained in t 80% of the rats during that time period. 
Experimental groups. Three groups of 23 cannulated 
animals were studied: group I, ad libitum-fed normal rats 
(n = 12); after a period of 5-7 days the animals were 
restudied as group II, 3-days starved rats (n = 6) and 
group 111, ad libitum-fed streptozotocin-treated (65 mg/ 
kg) 3-days diabetic rats (n = 6). In this way, each rat 
from groups II and 111 served as its own control. The 
starved rats from group II had free access to drinking 
water, and consumption of feces was prevented. The rats 
in group III were made diabetic by means of an intra- 
arterial injection of 65 mg/kg streptozotocin (Zanosar; 
Upjohn, Kalamazoo, MI) diluted in 0.01 M citrate buffer 
(pH 4.5). The streptozotocin solution (+300 ~1) was 
injected gradually over a time period of 5 min. Three 
days after streptozotocin injection, the diabetic rats were 
clamped. Rats were considered diabetic and suitable for 
clamp studies when 12-h fasting plasma glucose was 
between 20 and 30 mM. In vivo insulin action was 
measured by means of a four-step sequential (dose-re- 
sponse) hyperinsulinemic euglycemic (6 mM) clamp 
technique. 
An additional group of normal (n = 6), 3-days diabetic 
(n = 6), and 3-days starved (n = 5) rats was introduced 
and clamped at euglycemia (6 mM) and hyperinsulinemia 
(1 single insulin infusion step of 16 mU/min) to check 
the possible “self-exacerbating,” “insulin treatment,” and 
“glucose feeding” effect of sequential clamps, as previ- 
ously discussed by Bergman et al. (1) and Doberne et al. 
(7). The six normal rats used for the one-step clamp 
study were restudied after 1 wk as the diabetic group 
after they had been treated with streptozotocin as de- 
scribed. These one-step clamps lasted for 120 min, were 
performed under comparable conditions as described be- 
low for the sequential clamps, and were carried out at 
the end of the afternoon to match the time of clamping 
during the day with the maximal insulin infusion step as 
part of the sequential clamp. Possible effects of circadian 
rhythm in glucose metabolism were evaded in this way. 
Euglycemic clamp studies. Food was withdrawn, if ap- 
plicable, 12 h before the clamp was performed. One hour 
before clamping, the venous and arterial cannulae were 
aspirated, the venous line was filled with a 0.9% NaCl 
solution, and the arterial line was filled with a 0.9% NaCl 
solution containing 5 IU/ml heparin. The double-lumen 
swivel, allowing separate fluid infusions, was connected 
to two peristaltic pumps (Watson Marlow 202U/AA, 
Falmouth, UK). One venous line was used for the infu- 
sion of a 20% glucose solution at a variable rate, and the 
other line was used for a combined infusion of [3-3H] - 
glucose (Du Pont-NEN, Boston, MA, sp act 13.5 Ci/ 
mmol) and insulin (Actrapid porcine insulin; Nova, Co- 
penhagen, Denmark) at a constant rate (400 pi/h). The 
carotid cannula was connected to blood-sampling tubing, 
which allows frequent sampling of arterial blood and 
repletion of blood loss by means of fresh prewarmed 
whole blood obtained from littermates. The transfusion 
blood contained 3 mg/ml citrate to prevent clotting. 
Citrate was chosen instead to heparin to avoid possible 
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activation of lipoprotein lipase during the clamp. 
Before start of the insulin clamp, a bolus (3 &i) 
continuous (0.05 &i/min) infusion of [3-3H Jglucose was 
initiated and continued throughout the study. The bolus 
amount for diabetic rats was 6 &i. At 70, 80, and 90 
min, blood samples were collected to measure plasma 
glucose (n = 3), insulin (n = Z), and tritiated glucose 
specific activity (n = 3). Subsequently, a sequential four- 
step hyperinsulinemic euglycemic glucose clamp was 
started in periods of 90 min at increasing insulin infusion 
rates of 0.5, 1, 3, and 16 mU/min. A bolus of insulin was 
given before each insulin infusion period (2.5, 5, 15, and 
80 mu). Blood (40 ~1) was collected at 5- to lo-min 
intervals for fast determination of plasma glucose so the 
variable 20% glucose infusion could be adjusted to reach 
and maintain plasma glucose at 6 mM according to the 
negative feedback principle (6). During steady state, the 
final 20 min of each insulin infusion period, blood sam- 
ples were taken at lo-min intervals for plasma insulin 
(n = Z), plasma glucose (n = 3), and tritiated glucose 
specific activity (n = 3). During the first 15 min of each 
individual insulin infusion step, three samples of 0.7 ml 
titrated donor blood were transfused to the rat, compen- 
sating previous blood lo.ss. 
In previous studies, it was shown that hyperglycemia 
per se will enhance insulin-mediated glucose uptake by 
a mass action effect (5) and that glucose clearance is 
dependent of the prevailing blood glucose concentration 
(18). Therefore, all clamp experiments were carried out 
at matched glycemia. During the first insulin infusion 
step, in starved rats, plasma glucose was quickly raised 
(&lo min) from k4.5 to 6 mM by means of 20% glucose 
infusion and was gradually lowered in diabetic rats from 
t20 to 6 mM (in a time period of ,t90 min) by means of 
the insulin infusion of 0.5 mU/min. Because of this 
matched glycemia during the clamp between normal, 
starved, and diabetic rats, the first insulin infusion step 
(0.5 mU/min) lasted in fact for 90, 100, and 180 min, 
respectively. In diabetic rats, plasma samples for corti- 
costerone, glucagon, epinephrine, and norepinephrine 
were collected before and immediately after lowering 
plasma glucose from t20 to 6 mM. After these blood 
samples had been taken, an equal volume of transfusion 
blood was given. During and after the clamp, urine was 
collected for the estimation of urinary glucose. 
ChemicaZ determinations. Blood samples (40 ~1) for 
glucose determinations were collected in heparinized 
tubes and immediately centrifuged in a microcentrifuge 
(Beckman Instruments, Palo Alto, CA). Plasma glucose 
was measured by the glucose oxidase method (Glucose 
Analyzer II, Beckman Instruments). Blood samples (150 
~1) for insulin were transferred to chilled (OOC) heparin- 
ized tubes, centrifuged within 5 min, and plasma was 
removed and stored at -8OOC until assay. Insulin was 
measured in duplicate by a specific rat radioimmuno- 
assay (19), rendering identical standard curves for rat 
and porcine insulin. Intra- and interassay variations of 
the insulin assay were 6.8 and 8.1%, respectively, with 
an assay sensitivity of 2 pU/ml. Samples for determina- 
tion of catecholamines (CA) and corticosterone (250 ~1) 
were transferred to chilled (OOC) heparinized tubes con- 
taining 10 ~1 of a solution of 25 mg/ml disodium EDTA 
to prevent CA degradation and were centrifuged imme- 
diately. Plasma was removed and stored at -80°C until 
assay. The concentrations of norepinephrine and epi- 
nephrine were measured in duplicate in 20 ~1 perchloric 
acid-deproteinized plasma according to a radioenzymatic 
catechol-0-methyltransferase (COMT) procedure (39). 
The CAs were converted into their 3H methoxy deriva- 
tives by incubation with S-[methyl-3H]adenosyl-~-me- 
thionine (80 Ci/mmol; NEN) in the presence of COMT. 
Labeled products were isolated by organic extraction and 
paper chromatography. After elution of labeled products, 
activity was counted in a liquid scintillation analyzer 
(Philips; Eindhoven, The Netherlands). The intra- and 
interassay variabilities were <lo and 15%, respectively. 
The sensitivity of the assay (amount corresponding to 
two times the blank) was 1 pg for both norepinephrine 
and epinephrine. Plasma corticosterone concentrations 
were determined in duplicate according to a competitive 
protein-binding method (27). Corticosterone was ex- 
tracted with dichloromethane from 25-~1 samples of 
plasma, and the dry residue was incubated with a corti- 
costeroid-binding globulin tracer solution (0.1% plasma 
from adrenalectomized female rats containing [ 1,2-3H] 
corticosterone (40-50 Ci/mmol) as tracer}. Unbound ste- 
roid was removed using dextran-coated charcoal. Stand- 
ard corticosterone was supplied by Sigma (St. Louis, 
MO). The intra- and interassay coefficients of variation 
were <lo%. 
Blood samples (250 ~1) for glucagon were transferred 
to chilled (0°C) heparinized tubes, supplemented with 
5% Trasylol (10,000 Kallikrein inactivator units/ml; 
Bayer, Leverkusen, Germany) to prevent hormone deg- 
radation and were centrifuged immediately. Plasma was 
removed and stored at -80°C until assay. Plasma glu- 
cagon concentrations were determined in duplicate by a 
radioimmunoassay (Daiichi, Tokyo, Japan). The limit of 
detection was 15 pg/ml, with an interassay coefficient of 
variation of 8.6%. Plasma for [3-3H]glucose radioactivity 
(150 ~1) was the deproteinized by barium hydroxide-zinc 
sulfate (Somogyi procedure). The supernatant was evap- 
orated to dryness at 60°C to eliminate tritiated water 
and was counted for 10 min in a beta-scintillation coun- 
ter (LKB, Woerden, The Netherlands). 
Calculations. The rate of exogenous infused glucose to 
maintain euglycemia during the steady-state period (final 
20 min) of each individual insulin infusion step was used 
for the assessment of insulin action. All calculations were 
carried out in this period when the total amount of 
glucose taken up by all tissues of the body is equal to the 
input of glucose into the body. During this steady state, 
when the rate of glucose appearance (R,) is equal to the 
rate of glucose disappearance (RJ, the glucose turnover 
rate (=R,=Rd in mg/min) was calculated by dividing the 
[3-3H]glucose infusion rate (dpm/min) by the steady- 
state value of glucose specific activity (dpm/mg). Under 
these conditions, the glucose turnover rate is equal to 
the sum of the rates of exogenous infused glucose and of 
hepatic glucose production (HGP). From this equation 
the rate of HGP can be calculated. Because urinary 
glucose loss was not present, whole body glucose uptake 
(BGU) = glucose turnover rate = exogenous glucose 
infusion rate + rate of HGP. In the basal state the rate 
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of HGP (R,) is equal to Rd. terone were measured. Table 2 shows that, in diabetic 













normoglycemia in-a time period of &90 min did not result 
in a rise of insulin counterregulatory hormones. In fact, 
els vs. the corresponding rates of glucose uptake and plasma glucagon levels decreased by 37%, similar to the 
production, respectively. decrease observed in normal rats. In the basal state 
Maximum effect of insulin (insulin responsiveness) (insulin infusion rate of 0 mU/min), plasma norepineph- 
was assumed to exert at the insulin infusion rate of 16 rine, epinephrine, and glucagon concentrations were sim- 
mU/min, resulting in plasma insulin levels of &5,000 ilar in diabetic and normal rats. Only basal plasma 
pU/ml. The index for insulin sensitivity [half-maximal corticosterone levels were increased in diabetic rats as 
effective dose (ED&] was calculated from the individual compared with normal rats. For this reason, we also 
dose-response curves. 
Data analysis. Hormone-stimulated 
measured basal plasma corticosterone 
starved rats. These turned out to be responsiveness is 
levels in the six 
11.1 t 4.7 pg/dl, 
defined as the maximal response, and sensitivity is de- which is not significantly different from normal and 
termined by the position of the curve and is defined as diabetic rats. In normal rats maintaining euglycemia the 
the hormone concentration giving EDs0. EDs0 was deter- elevation of plasma insulin from 22.7 to 42.4 pU/ml had 
mined by linearizing the ascending or descending part of no effect on the levels of the measured adrenal and 
the dose-response curve, as described previously (19). In sympathetic hormones (Table 2). 
In vivo dose-response relationship between plasma in- 
of diabetic rats is unchanged, compared with normal 
sulin levels and stimulation of whole body glucose uptake. 
Figure 1 depicts the curves for BGU determined by the 
rats. The ED50 values for BGU, which characterize the 
sequential hyperinsulinemic euglycemic (dose-response) 
clamp using normal, starved, and diabetic rats. These 
position of the curves, are given in Table 3. The EDs0 
curves reveal that maximal insulin-stimulated BGU is 
values were calculated by linearizing the individual dose- 
unchanged (12.4 t 0.8 mg/min, P < 0.01) in starved but 
is decreased (8.5 t 0.8 mg/min, P c 0.05) in diabetic 
compared with normal rats (12.3 t 0.7 mg/min). These 
values are reached at similar plasma insulin levels of 
5,340 t 776, 4,615 t 907, and 5,435 t 831 pU/ml, 
respectively. The curve of the starved rats has shifted to 
the left (P < 0.05), but the relative position of the curve 
short, the biological effect at each hormone concentra- 
tion is calculated, is expressed as a percentage of the 
maximal response, and is denoted y. The logarithm of y/ 
(100 - y) is plotted against the logarithm values for the 
hormone concentration. This so-called log-logit plot 
gives a straight line that can be evaluated by linear 
regression analysis according to the method of least 
squares. EDso is determined by the intercept of the line 
with the ordinate. 
rion of significance was set at P C 0.05. Statistical 
Data are expressed as means t SE. Comparisons be- 
tween two groups were made using the paired or unpaired 
analysis and construction of Figs. 1 and 2 and Tables l- 
Student t tests, when 
3 were performed on an Apple Macintosh computer. 
appropriate. The Bonferroni ad- 




tal animals. Three-days st 





and low fasting plasma insulin levels compared with 
normal rats. However, fasting plasma glucose levels and 
HGP were low in starved rats but high in diabetic rats. 
When HGP was expressed per gram wet liver weight, 
HGP was unchanged in starved but increased in diabetic 
compared with normal rats (Table 1). 
Glycemia-related levels of insulin counterregulatory 
hormones. To exclude the possibility that in vivo insulin 
response curves by means of the log-logit method (see 
MATERIALS AND METHODS). Goodness of fit was excel- 
lent, as judged from the correlation coefficients of the 
regression lines: 0.98 t 0.01, 0.98 t 0.01, and 0.95 t 0.02 
in normal, starved, and diabetic rats, respectively. 
In vivo dose-response relationship between plasma in- 
sulin levels and inhibition of hepatic glucose production. 
Figure 2 depicts the curves for HGP, determined by the 
sequential hyperinsulinemic euglycemic (dose-response) 
clamp using normal, starved, and diabetic rats. From 
these curves, it is clear that maximal insulin-inhibited 
HGP is identical among normal (-0.5 t 0.2 mg/min), 
action in diabetic rats was influenced by a rise in insulin starved (-0.3 t 0.4 mg/min), and diabetic (-0.4 t 0.4 
counterregulatory hormones related to the induction of mg/min) rats. The curve of the diabetic rats has shifted 
a relative hypoglycemia at the start of the clamp, levels to the right (P < 0.05), whereas the relative position of 
of norepinephrine, epinephrine, glucagon, and corticos- the curve of the starved rats is unchanged compared with 
TABLE 1. Characteristics of normal, starved, and diabetic rats at start of 4-step sequential 























12 347t4.3 NA 5.9t0.3 16.9k2.6 3.0t0.2 15.4t0.8 
6 299t4.8* 14 4.8*0.4* 7.5*1.8* 2.1*0.2* 9.1&0.4* 
6 310*4.5* 10 22.1t1.9” 5.7t2.4* 5.4t0.5* 14.720.8 
Values are means k SE. Wet liver wt was determined in a separate set of experimental rats held under identical 
starved, and 6 diabetic rats were used. NA, not applicable. * Significant difference from corresponding normal value. 
conditions. Six normal, 6 
INSULIN ACTION DURING STARVATION AND DIABETES E829 
TABLE 2. Levels of counterregulatory hormones during basal conditions and during first step 



















Normal rats basal 6.1kO.3 22.7t4.2 57.6t9.3 404t42 178-1-22 9.6t3.1 
Normal rats first step 6.0t0.2 42.4t3.4* 45.7tl3.0* 430t46 163&26 12.5t5.2 
Diabetic rats basal 22.1+1.9? 5.7k2.4t 69.1220.3 450t51 191*29 17.7+3.8-l- 
Diabetic rats first step 6.2&0.3* 33.2&3.8* 43.6t4.7* 512t56 202t39 21.7+4.8? 
Values are means & SE. Insulin infusion was 0 mU/min during basal conditions and 0.5 mU/min during first step of sequential clamp. In 
diabetic rats this means before and after reduction of plasma glucose levels from fasting hyperglycemia to euglycemia. * Significant difference 
from corresponding basal value. t Significant difference from corresponding normal value 
E 




. - starved 
. --L diabetic 
II 
1 IO 100 1000 100 00 
plasma insulin (plJ/ml) 
FIG. 1. Dose-response curves for steady-state plasma insulin levels 
and whole body glucose uptake as determined with sequential hyper- 
insulinemic euglycemic clamp technique in normal, starved, and strep- 
tozotocin-treated diabetic rats. Each point represents mean * SE. 
TABLE 3. Sensitivity for insulin-stimulated whole body 
glucose uptake and insulin-inhibited hepatic glucose 
production in normal, starved, and diabetic rats 
Animals n 





12 105*10 71t5 
6 70t11* 68tlO 
6 113k21 157+211‘ 
Values are means 2 SE. EDs0, half-maximal effective dose; BGU, 
whole body glucose uptake; HGP, hepatic glucose production. * Signif- 
icant difference from normal value, P c 0.005. 5 Significant difference 
from normal and starved values, P < 0.01. 
normal rats. The EDso values for HGP are given in 
Table 3. The EDso values were calculated by linearizing 
the individual dose-response curves by means of the log- 
logitmethod (see MATERIALS AND METHODS). Goodness 
of fit was excellent, as judged from the correlation coef- 
ficients of the regression lines: 0.95 t 0.02, 0.97 t 0.01, 
and 0.94 t 0.02 in normal, starved, and diabetic rats, 
respectively. 
The possible self-exacerbating, glucose feeding, and in- 
sulin treatment effect of sequential clamps. To determine 
whether antecedent infusion of insulin (and glucose) had 
altered insulin responsiveness for BGU and HGP (deter- 
- diabetic 
2 -1 !  ' ' """I ' ' ""~'I ' ' """I ' 1 " ,,rrl 
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FIG. 2. Dose-response curves for steady-state plasma insulin levels 
and hepatic glucose production as determined with sequential hyper- 
insulinemic euglycemic clamp technique in normal, starved, and strep- 
tozotocin-treated diabetic rats. Each point represents mean t SE. 
mined during the final and maximal insulin infusion step 
of the sequential clamp), we performed additional one- 
step clamps at maximal plasma insulin concentrations 
in normal, starved, and diabetic rats. One-step clamps in 
normal, starved, and diabetic rats at maximal plasma 
insulin levels of 6,563 t 726, 7,268 t 410, and 5,862 t 
1,015 pU/ml resulted in a BGU of 12.4 t 0.4, 12.3 t 1.3, 
and 7.7 t 0.3 mg/min and in a HGP of 0.2 t 0.5, -0.1 t 
0.3, and 0.1 & 0.5 mg/min, respectively. This is similar 
to the values reached during the sequential clamps in 
this study. For data, see text describing Figs. 1 and 2. 
DISCUSSION 
During insulinopenic diabetes, hyperglycemia is ac- 
companied by a marked catabolic state (19). In the past 
decade, several experiments have been performed to un- 
ravel the effect of catabolism on insulin action (10, 19, 
29, 44). Starvation was used as a model to create insu- 
linopenia and catabolism. To determine the role of ca- 
tabolism on in vivo insulin action in diabetic rats, we 
studied, apart from diabetic rats, a group of starved rats 
that showed similar bodyweight reduction. 
A second goal of this study was to discriminate between 
insulin sensitivity (ED& and insulin responsiveness 
(maximal response) during the clamp. This discrimina- 
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tion is important because it leads to a better understand- 
ing of the mechanism of insulin action. In general, a 
decrease in insulin responsiveness is due to a defect that 
is rate limiting for insulin action. A decrease in insulin 
sensitivity is due to a defect(s) in steps of insulin action 
that are not rate limiting. 
Insulin action was studied with the sequential hyper- 
insulinemic euglycemic clamp technique in conscious 
unrestrained rats. This technique was combined with a 
continuous infusion of [ 3-3H] glucose, allowing calcula- 
tion of whole body glucose turnover to discriminate be- 
tween the stimulating effect of insulin on whole body 
glucose uptake and the inhibiting effect of insulin on 
hepatic glucose production (1, 29, 34). 
In this study, two groups of highly catabolic and in- 
sulinopenic animals, i.e., 3-days starved and streptozo- 
tocin-treated &days diabetic rats, showed opposite ef- 
fects on in vivo insulin action. Starved rats revealed 
increased insulin sensitivity but normal responsiveness 
for whole BGU when compared with normal rats. The 
increased sensitivity is consistent with the findings of 
Penicaud et al. (29), but responsiveness was normal in 
our rats and was reduced in their starved rats. The reason 
for this discrepancy might be that we used mature and 
more obese rats (300-350 g), whereas Penicaud et al. (29) 
used young and lean rats (150-200 g). Compared with 
young and lean rats, mature and rather obese rats show 
a more pronounced protein and fuel metabolism sparing 
effect during a 3-day period of starvation (8-10). The 
increased sensitivity is paralleled and might be explained 
by an increased binding of insulin to muscle, suggesting 
an increased insulin receptor number and/or affinity, as 
determined by Le Marchand-Brustel and Freychet (22). 
Normal insulin responsiveness for BGU indicates that 
starvation for 3 days using rats of -350 g causes no 
insulin resistance at the postbinding level [mechanism 
discussed by Rizza et al. (3l)]. However, in diabetic rats, 
insulin sensitivity for BGU was unaltered, and insulin 
responsiveness was decreased. The latter suggests that, 
in diabetic rats, insulin resistance is located at the post- 
binding level, as shown before (28). Insulin sensitivity 
was unaltered, which is in agreement with an in vivo 
study of Nishimura et al. (28) and an in vitro study of 
Goto et al. (11) using soleus muscle. This unaltered 
sensitivity is observed although the number of insulin 
receptors and/or affinity of insulin receptors for insulin 
in muscle is increased (22, 28). This suggests that addi- 
tional postbinding processes determine the ultimate sen- 
sitivity of BGU for insulin. 
Summarizing our results, we conclude that the severe 
catabolic state (body weight loss after a 3day period of 
starvation and diabetes was lo-15%) and insulinopenia 
are not responsible for the diabetes-related insulin re- 
sistance. On the contrary, severe catabolism present in 
starved animals is accompanied with an increase in in- 
sulin action. 
Although both diabetic and starved animals had simi- 
lar weight loss, suggesting similar catabolic states, the 
mechanism of catabolism might be different. There could 
have been a difference in free fatty acid (FFA) levels 
before and during the clamp studies. Given the fact that 
FFA levels can inhibit insulin-mediated glucose uptake 
(21) and if FFA levels were higher during the clamp 
studies in diabetic vs. starved animals, this might have 
influenced the shape of the dose-response curve. How- 
ever, this seems unlikely since we have previously shown 
that adipocytes from both starved and diabetic rats are 
not resistant to the antilipolytic action of insulin and 
that lipolysis is identically suppressed by insulin (19). 
After 7.5 h of clamping, plasma FFA levels are therefore 
expected to be decreased to a similar extent in starved 
and diabetic animals. Thus the difference in in vivo 
insulin responsiveness between starved and diabetic rats 
is probably not caused by a difference in FFA levels. 
The striking difference between starved and diabetic 
rats is the prevailing glycemia. Recently, evidence was 
presented that hyperglycemia per se contributes to the 
impairment of in vivo insulin-mediated glucose disposal 
in diabetes. Rossetti et al. (34) showed that correction of 
hyperglycemia with phlorizin normalized in vivo insulin 
action in diabetic rats, and Yki-Jarvinen et al. (45) 
revealed that short-term (24-h) hyperglycemia in type I 
diabetic patients reduced tissue glucose uptake, as meas- 
ured with the glucose clamp technique. This and the fact 
that starved rats with low plasma glucose levels show an 
increase in in vivo BGU suggest that an in vivo autoreg- 
ulation of glucose utilization exists. This is consonant 
with our previous in vitro experiments with preadipo- 
cytes (40) and with soleus muscle by others (37), which 
revealed that glucose regulates its own transmembrane 
transport and glycolytic flux. In this context, defects in 
glucose transport have been described in a similar dia- 
betic rat model of insulin resistance (33, 47), suggesting 
that glucose transport may be the rate-limiting step for 
BGU. Other defects, such as defects in glycogen synthesis 
(33), have also been described, indicating that this issue 
is complicated and needs further investigation. It has 
been suggested that insulin and glucose delivery (blood 
flow) to skeletal muscle may be rate limiting for BGU. 
If blood flow were reduced in diabetic rats, this could 
give the appearance of a decrease in insulin responsive- 
ness. This possibility cannot be excluded, but this expla- 
nation seems unlikely, since James et al. (14) have shown 
that blood flow is not a major determinant of insulin- 
mediated glucose uptake in muscle of rats, as studied by 
means of the hyperinsulinemic euglycemic clamp tech- 
nique. 
The use of conscious rats allowed us to study insulin 
counterregulatory hormones in the absence of anaes- 
thesia-induced disturbances of the central nervous sys- 
tem. The lowering of plasma glucose from 21.3 to 6.0 
mM using an insulin infusion rate of 0.5 mU/min, during 
the clamp in diabetic rats, did not elicit a response of 
counterregulatory hormones. We investigated the effect 
of induction of relative hypoglycemia because Santiago 
et al. (36) have shown that, during diabetes, there is no 
absolute plasma glucose concentration threshold for ac- 
tivation of glucose counterregulatory systems. Before and 
immediately after the decline of glycemia, plasma nor- 
epinephrine, epinephrine, glucagon, and corticosterone 
levels behaved in the same way as in normal euglycemic 
rats during the insulin infusion of 0 and 0.5 mU/min. 
Thus the measured in vivo insulin action in diabetic rats 
was not influenced by a rise in counterregulatory hor- 
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mones related to the induction of a relative hypoglyce- 
mia. In both normal and diabetic rats the insulin infusion 
of 0.5 mU/min caused 1) a similar decrease in plasma 
glucagon levels, suggesting that in 3-days diabetic rats 
the suppressive effect of insulin on plasma glucagon 
levels is intact and 2) no effect on plasma norepineph- 
rine, epinephrine, and corticosterone levels. It has been 
reported that an elevation of plasma insulin levels results 
in activation of the sympathetic nervous system (35). We 
cannot support this observation, but the possibility exists 
that higher insulin levels than used in our study (*50 
pU/ml) are needed to elicit a response of plasma norep- 
inephrine levels. During the clamp studies of James et 
al. (13), using high insulin levels, there was no effect on 
epinephrine levels, which is in agreement with our ob- 
servations. Corticosterone levels in diabetic rats were 
elevated compared with normal rats, suggesting that the 
induction of diabetes promotes the appearance of this 
adrenal glucocorticoid stress hormone. This raises the 
question of whether this could explain the in vivo hepatic 
insulin insensitivity and the decrease in insulin respon- 
siveness for BGU in diabetic rats. The fact that we did 
not observe a significant difference in corticosterone 
levels between diabetic and starved rats (which show 
increased insulin action) suggests that an increase in 
corticosterone concentrations of a magnitude as meas- 
ured in this study is of minor importance on insulin 
action. Furthermore, it seems that the effect of gluco- 
corticosteroids on in vivo insulin action is primarily 
directed toward a decrease of insulin sensitivity and not 
of insulin responsiveness (32). 
We have not measured the levels of glucagon, epineph- 
rine, and norepinephrine in starved rats, but, from an- 
other study using a comparable experimental set up, we 
know that 3 days of food deprivation has no effect on 
resting plasma catecholamine levels (43). 
Basal HGP was reduced by 30% in starved compared 
with normal rats which is similar to the reduction ob- 
served by Issad et al. (12). This 30% reduction is paral- 
leled by a similar reduction in wet liver weight. Thus, 
expressed per gram of liver weight, HGP is identical 
between normal and starved rats, indicating that there 
is no defect in liver glucose metabolism. This is supported 
by our observation that insulin-inhibited HGP is normal 
in starved rats. In diabetic rats, basal HGP was doubled 
compared with normal rats (without a change in wet liver 
wt), indicating that hyperglycemia per se is no longer 
able to suppress HGP during insulin-deficient diabetes. 
Muller et al. (26) described that, in the normal physio- 
logical situation, hyperglycemia reduces HGP independ- 
ently of hormonal changes. 
Our study reveals that diabetic rats show in vivo 
hepatic insulin insensitivity. This seems to be caused, at 
least partially, by decreased autophosphorylation of the 
insulin receptor kinase (15). This indicates that signal 
transduction per insulin receptor is reduced, a defect that 
can be overcome by adding surplus insulin, since a max- 
imal biological effect of insulin is normally achieved 
when only 10% of the total receptor population is occu- 
pied by insulin. By occupying more receptors the signal 
becomes strong enough to reach a maximal effect. This 
could explain why we do not observe a defect in hepatic 
insulin action at maximal plasma insulin concentrations. 
The self-exacerbating effect of sequential clamps on 
the biological action of insulin, as described previously 
(7), was not observed during our experiments. Stimula- 
tion of BGU and inhibition of HGP at maximal insulin 
concentrations were similar during sequential or one- 
step clamps in normal, starved, and diabetic rats. This 
is consistent with the findings of Proietto et al. (30) and 
Rizza et al. (31) who showed that a precise insulin dose- 
response curve can be constructed in 1 single day by 
means of the sequential hyperinsulinemic euglycemic 
clamp technique. Insulin treatment of diabetic rats and 
glucose (re)feeding of starved rats, conditions that are 
present during sequential (long-term) clamping, are 
known to improve insulin action (16, 17, 42). However, 
from several studies (3, 23), we know that this improve- 
ment does not take place before a time period of 4-6 h. 
Since our clamp studies take 6-7.5 h, this could explain 
why we do not observe an effect of long-term clamping 
on insulin’s maximal biological effect in diabetic and 
starved rats. 
In summary, insulin resistance in diabetic rats is 
caused by hepatic insensitivity and by a reduction of 
whole body responsiveness, and starved rats show normal 
hepatic insulin action but increased whole body insulin 
sensitivity. We conclude that 3-days starved and diabetic 
rats, both suffering from a comparable catabolic state 
(lo-15% body wt loss), show opposite effects on in vivo 
insulin action. This indicates that in vivo insulin resist- 
ance in diabetic rats is not caused by the catabolic state 
per se. 
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